48LOW

COV

CLEO DIAGN FPO [COV]
Cleo Diagnostics Ltd, a biotechnology company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property, testing the IP, and securing patents. Cleo Diagnostics Ltd was incorporated in 2021 and is based in Melbourne, Australia.
Healthcare · ASX Small Cap
$0.5250 -4.6%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical64
Catalyst55
Sentiment50
Fundamental65
Momentum76
Risk Gate46
Get alerts when COV's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track COV — Free

Active Signals

Bullish Signals

  • MACD momentum is picking up steam
  • Watch out — volume is flowing out even as price holds up. Distribution pattern
  • Trading above the 200-day average — the long-term trend is on your side
  • Strong cash runway (15 quarters)
  • 4C filed 2026-01-28
  • Strong revenue growth (+373%)
  • Small-cap ($20-100M)
  • Sentiment is mixed — no strong consensus either way
  • Strong long-term momentum — up 60% over the past year (excluding last month)
  • Revenue growing at +373% — the top line is moving in the right direction
  • Altman Z-Score grey zone (1.88, low-confidence approx)
  • RBA hiking (-3pts)

Risk Signals

  • Deeply negative margins (-157%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about COV
"What's driving COV's score?" "How does COV compare to peers?" "Key risks for COV?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE CLEO Optimises Biomarker Panel Ahead of FDA Submission
NONE Appendix 4D and Half Yearly Accounts
NONE CLEO Confirms Next-Gen Platform for Ovarian Cancer Test
Announcement tone +5pts

Recent ASX Announcements

2026-03-22 CLEO Optimises Biomarker Panel Ahead of FDA Submission PRICE SENSITIVE
2026-02-25 Appendix 4D and Half Yearly Accounts PRICE SENSITIVE
2026-02-17 CLEO Confirms Next-Gen Platform for Ovarian Cancer Test PRICE SENSITIVE
2026-01-28 Quarterly activities and cashflow report PRICE SENSITIVE

Key Metrics

$71.9M
Market Cap
194K
Avg Volume
0.9x
Vol Ratio
$0.31 — $0.90
52-Week Range
N/A
Short Interest
15 qtrs
Cash Runway
-49.6%
ROE
-157.4%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 60%
LLeader vs LaggardlaggardRS: -3
IInstitutional Sponsorshipinsufficient_dataInst: 0%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #53 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:COV vs ATXCOV vs PNVCOV vs IMM
Scout Pro — Deeper Analysis for COV
Try Pro free for 30 days
Share this analysis

Track COV and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required